This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.08% per year. These returns cover a period from January 1, 1988 through May 6, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Zacks News
Here's Why Investors Should Retain ResMed (RMD) Stock for Now
by Zacks Equity Research
Investors continue to be optimistic about ResMed (RMD) due to the sustained growth in the SaaS business.
Thermo Fisher (TMO) Launches New Solutions for Clinical Labs
by Zacks Equity Research
Thermo Fisher (TMO) introduces the KingFisher Apex Dx system and Applied Biosystems MagMAX Dx Isolation Kit to improve preanalytical workflows for clinical laboratories.
Edwards Lifesciences (EW) Forwards Growth Strategy and Outlook
by Zacks Equity Research
Edwards Lifesciences' (EW) TAVR remains strong, driven by greater awareness, patient activation and advances in new technologies such as RESILIA.
Are Medical Stocks Lagging Arch Therapeutics (ARTH) This Year?
by Zacks Equity Research
Here is how Arch Therapeutics, Inc. (ARTH) and Haemonetics (HAE) have performed compared to their sector so far this year.
Illumina (ILMN) Expands Globally Despite Macroeconomic Woes
by Zacks Equity Research
The NovaSeq X launch strengthens Illumina's (ILMN) competitive position in high-throughput sequencing.
Walgreens' (WBA) AllianceRx Pharmacy Will Now Distribute XDEMVY
by Zacks Equity Research
Walgreens' (WBA) subsidiary, AllianceRx Walgreens Pharmacy, is one of the four specialty pharmacies selected to distribute XDEMVY.
BrainsWay (BWAY) Strengthens South Korean Foothold With Deep TMS
by Zacks Equity Research
BrainsWay's (BWAY) Deep TMS targets affected brain structures with a magnetic field, stimulating crucial neural networks.
Quest Diagnostics (DGX) & CDC to Assess Hepatitis C Burden
by Zacks Equity Research
Quest Diagnostics (DGX) and CDC expand research collaboration to better understand the Hepatitis C burden in the United States.
Here's Why You Should Retain Boston Scientific (BSX) Now
by Zacks Equity Research
Investors are optimistic about Boston Scientific (BSX) on strong worldwide demand for its GI and pulmonary treatment options and traction in Europe for its next-generation WATCHMAN FLX.
Globus Medical (GMED) Gains From NuVasive Deal, Macro Woes Stay
by Zacks Equity Research
Globus Medical (GMED) witnesses notable gains across its product portfolio in expandables, biologics, MIS screws, 3D printed implants and cervical offerings.
OrthoPediatrics (KIDS) Introduces Unit for Non-Surgical Bracing
by Zacks Equity Research
OrthoPediatrics (KIDS) continues to diversify its non-surgical offerings with the introduction of the DF2 Brace.
Here's Why You Should Retain National Vision (EYE) Stock Now
by Zacks Equity Research
Investors are optimistic about National Vision's (EYE) stock, banking on comparable store sales growth and a favorable liquidity structure.
Tandem Diabetes (TNDM) Launches Dexcom G7 Integrated t:slim X2
by Zacks Equity Research
Tandem Diabetes' (TNDM) t:slim X2 is the first AID system in the world to feature Dexcom's most advanced CGM technology.
Omnicell's (OMCL) Global Expansion Strong, Macro Issues Ail
by Zacks Equity Research
Omnicell (OMCL) accelerates a shift to cloud-based solutions and tech-enabled services through the launches of Inventory Optimization Service and Central Pharmacy Dispensing Services.
Neogen (NEOG) to Offer Biosecurity Products With New Pact
by Zacks Equity Research
Neogen will be able to highlight its biosecurity and horse health products, like the COMPANION range of cleansers and disinfection solutions, through the latest collaboration.
Here's Why You Should Retain Align Technology (ALGN) Stock Now
by Zacks Equity Research
Investors are optimistic about Align Technology (ALGN) on global expansion and strategic alliance.
Teleflex (TFX) Signs Peripheral Access Purchasing Deal With PINC
by Zacks Equity Research
Teleflex (TFX) secures the Peripheral Access purchasing agreement with Premier, Inc.
Why Haemonetics (HAE) is a Top Value Stock for the Long-Term
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Integra Gains From New Product Launches, Mounting Costs Ail
by Zacks Equity Research
Integra expands the international reach of the CUSA platform and registers DuraGen, DuraSeal, Mayfield and Duo LED lighting in the EMEA and Latin America.
Boston Scientific (BSX) Gains From Global Expansion, FX Woe Ails
by Zacks Equity Research
Boston Scientific's (BSX) Endoscopy business within MedSurg benefits from strong worldwide demand for its broad range of GI and pulmonary treatment options.
Henry Schein's (HSIC) Zahn Dental and Myerson Enter New Deal
by Zacks Equity Research
Henry Schein's (HSIC) dental laboratory business, Zahn Dental, is set to exclusively distribute Myerson's New Trusana 3D Premium Denture System.
Here's Why You Should Retain Charles River (CRL) Stock Now
by Zacks Equity Research
Charles River's (CRL) share price is likely to grow, backed by the strength of the DSA segment.
Exact Sciences (EXAS) Up 35.4% YTD: Will the Rally Continue?
by Zacks Equity Research
Investors are optimistic about Exact Sciences (EXAS), driven by growth in Screening and Precision Oncology segments.
Here's Why You Should Invest in Haemonetics (HAE) Right Now
by Zacks Equity Research
Investors are optimistic about Haemonetics (HAE) on consistent growth performance and raised guidance.
Thermo Fisher (TMO) Advances Health Equity via New Partnership
by Zacks Equity Research
Thermo Fisher (TMO) announces a collaboration with Project HOPE to improve health outcomes by enabling expanded access to HIV testing and support services in Nigeria.